Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead
Alvogen Is Also In The Race To Launch US Lenalidomide In 2022
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
You may also be interested in...
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.
Bristol Myers Squibb does not “expect generic entry in the US market prior to the first quarter of 2026” for its Pomalyst treatment for relapsed and refractory multiple myeloma, after reaching a settlement agreement with ANDA sponsor Dr Reddy’s Laboratories.
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.